Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats

Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental coli...

Full description

Saved in:
Bibliographic Details
Published in:BioMed research international 2019, Vol.2019 (2019), p.1-8
Main Authors: Triantafillidis, John K., Nomikos, Alexandros, Pittaras, Theodoros, Sideris, Michail, Korontzi, Maria, Chrysikos, Dimosthenis, Barbatis, Calypso, Papalois, Apostolos E., Triantafyllidi, Eleni
Format: Article
Language:English
Subjects:
Animals
Colitis
Colitis - drug therapy
Colon
Colonies
Colony-stimulating factor
Disease Models, Animal
Euthanasia
Gastroenterology
Granulocyte Colony-Stimulating Factor - pharmacology
Granulocyte-macrophage colony stimulating factor
Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology
Granulocytes
Granulocytes - drug effects
Growth factors
Humans
Inflammatory bowel disease
Inflammatory bowel diseases
Intestine
Lenograstim - pharmacology
Leukocytes (granulocytic)
Macrophage Colony-Stimulating Factor - pharmacology
Macrophages
Male
Malondialdehyde
Neutrophils
Oxidative stress
Physiology
Prednisolone
Rats
Rats, Wistar
Recombinant Proteins - pharmacology
Rodents
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23
cites cdi_FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23
container_end_page 8
container_issue 2019
container_start_page 1
container_title BioMed research international
container_volume 2019
creator Triantafillidis, John K.
Nomikos, Alexandros
Pittaras, Theodoros
Sideris, Michail
Korontzi, Maria
Chrysikos, Dimosthenis
Barbatis, Calypso
Papalois, Apostolos E.
Triantafyllidi, Eleni
description Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental colitis in rats. Methods. Experimental colitis was induced in 62 male Wistar rats, divided into 9 groups, using 2,4,6-trinitrobenzensulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment started 7 days after the induction of colitis. Animals were kept for 19 days. Group 5: Six animals with colitis. Treatment started 2 weeks after the induction of colitis. Group 6: Six animals with colitis, the same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8. Six animals with colitis, the same as in group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results. CSF and GSF administration significantly improved the histological score (P
doi_str_mv 10.1155/2019/8298192
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6803744</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2307965105</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23</originalsourceid><addsrcrecordid>eNqNkk9r3DAQxU1paUKaW89F0EtC143G9srWJVCW_INdCtv0bMby2KtgS1vJTrqfs1-oWna7TQuF6iLB_PTmDfOi6C3wjwDT6UXCQV4UiSxAJi-i4ySFLBaQwcvDO02PolPvH3g4BQguxevoKAVR5BmH4-jHvSMcejIDe9LDii1s1zrsrR90z86WpGxfaYOhfDv2aNiNQzN2Vm0GiheonF2vsCU2s501G_Yl_Bo7HLRp2TWqwboJW67Gto9nvpmwhabOtmTOGZqazcnY0GvX6bnuP8XO2V2_dvaRPLv6viant76x23bXg_ZMG7bEwb-JXjXYeTrd3yfR1-ur-9ltPP98czf7NI9VlsMQ50oKzJBIKZCQUKW4LORUNqCSmuoKVI0Km7riwCtAEFhBnogAyzyjKklPosud7nqseqpVMOOwK9fBF7pNaVGXf1aMXpWtfSxFwdM8y4LA2V7A2W8j-aHstVfUdWjIjr4MK0wSURRSBvT9X-iDHZ0J4wWK51JMgU8DNdlRYTHeO2oOZoCX28CU28CU-8AE_N3zAQ7wr3gE4MMOWGlT45P-TzkKDDX4m4YkLzKR_gQoGdgz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2307965105</pqid></control><display><type>article</type><title>Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats</title><source>Wiley Online Library Open Access</source><source>Publicly Available Content Database</source><creator>Triantafillidis, John K. ; Nomikos, Alexandros ; Pittaras, Theodoros ; Sideris, Michail ; Korontzi, Maria ; Chrysikos, Dimosthenis ; Barbatis, Calypso ; Papalois, Apostolos E. ; Triantafyllidi, Eleni</creator><contributor>Quinn, Frederick D. ; Frederick D Quinn</contributor><creatorcontrib>Triantafillidis, John K. ; Nomikos, Alexandros ; Pittaras, Theodoros ; Sideris, Michail ; Korontzi, Maria ; Chrysikos, Dimosthenis ; Barbatis, Calypso ; Papalois, Apostolos E. ; Triantafyllidi, Eleni ; Quinn, Frederick D. ; Frederick D Quinn</creatorcontrib><description>Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental colitis in rats. Methods. Experimental colitis was induced in 62 male Wistar rats, divided into 9 groups, using 2,4,6-trinitrobenzensulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment started 7 days after the induction of colitis. Animals were kept for 19 days. Group 5: Six animals with colitis. Treatment started 2 weeks after the induction of colitis. Group 6: Six animals with colitis, the same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8. Six animals with colitis, the same as in group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results. CSF and GSF administration significantly improved the histological score (P&lt;0.05) and reduced malondialdehyde contents (P&lt;0.05), compared to control groups in all animals. CSF was superior to GSF and to prednisolone. Conclusion. Administration of both CSF and GSF could significantly improve the histological score and oxidative stress in experimental colitis in rats.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2019/8298192</identifier><identifier>PMID: 31687401</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Animals ; Colitis ; Colitis - drug therapy ; Colon ; Colonies ; Colony-stimulating factor ; Disease Models, Animal ; Euthanasia ; Gastroenterology ; Granulocyte Colony-Stimulating Factor - pharmacology ; Granulocyte-macrophage colony stimulating factor ; Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology ; Granulocytes ; Granulocytes - drug effects ; Growth factors ; Humans ; Inflammatory bowel disease ; Inflammatory bowel diseases ; Intestine ; Lenograstim - pharmacology ; Leukocytes (granulocytic) ; Macrophage Colony-Stimulating Factor - pharmacology ; Macrophages ; Male ; Malondialdehyde ; Neutrophils ; Oxidative stress ; Physiology ; Prednisolone ; Rats ; Rats, Wistar ; Recombinant Proteins - pharmacology ; Rodents</subject><ispartof>BioMed research international, 2019, Vol.2019 (2019), p.1-8</ispartof><rights>Copyright © 2019 Apostolos E. Papalois et al.</rights><rights>Copyright © 2019 Apostolos E. Papalois et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2019 Apostolos E. Papalois et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23</citedby><cites>FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23</cites><orcidid>0000-0003-4398-7557 ; 0000-0002-9115-232X ; 0000-0002-4199-6700 ; 0000-0001-8339-7426 ; 0000-0001-5738-535X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2307965105/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2307965105?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,780,784,885,4024,25753,27923,27924,27925,37012,37013,44590,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31687401$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Quinn, Frederick D.</contributor><contributor>Frederick D Quinn</contributor><creatorcontrib>Triantafillidis, John K.</creatorcontrib><creatorcontrib>Nomikos, Alexandros</creatorcontrib><creatorcontrib>Pittaras, Theodoros</creatorcontrib><creatorcontrib>Sideris, Michail</creatorcontrib><creatorcontrib>Korontzi, Maria</creatorcontrib><creatorcontrib>Chrysikos, Dimosthenis</creatorcontrib><creatorcontrib>Barbatis, Calypso</creatorcontrib><creatorcontrib>Papalois, Apostolos E.</creatorcontrib><creatorcontrib>Triantafyllidi, Eleni</creatorcontrib><title>Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats</title><title>BioMed research international</title><addtitle>Biomed Res Int</addtitle><description>Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental colitis in rats. Methods. Experimental colitis was induced in 62 male Wistar rats, divided into 9 groups, using 2,4,6-trinitrobenzensulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment started 7 days after the induction of colitis. Animals were kept for 19 days. Group 5: Six animals with colitis. Treatment started 2 weeks after the induction of colitis. Group 6: Six animals with colitis, the same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8. Six animals with colitis, the same as in group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results. CSF and GSF administration significantly improved the histological score (P&lt;0.05) and reduced malondialdehyde contents (P&lt;0.05), compared to control groups in all animals. CSF was superior to GSF and to prednisolone. Conclusion. Administration of both CSF and GSF could significantly improve the histological score and oxidative stress in experimental colitis in rats.</description><subject>Animals</subject><subject>Colitis</subject><subject>Colitis - drug therapy</subject><subject>Colon</subject><subject>Colonies</subject><subject>Colony-stimulating factor</subject><subject>Disease Models, Animal</subject><subject>Euthanasia</subject><subject>Gastroenterology</subject><subject>Granulocyte Colony-Stimulating Factor - pharmacology</subject><subject>Granulocyte-macrophage colony stimulating factor</subject><subject>Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology</subject><subject>Granulocytes</subject><subject>Granulocytes - drug effects</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Inflammatory bowel disease</subject><subject>Inflammatory bowel diseases</subject><subject>Intestine</subject><subject>Lenograstim - pharmacology</subject><subject>Leukocytes (granulocytic)</subject><subject>Macrophage Colony-Stimulating Factor - pharmacology</subject><subject>Macrophages</subject><subject>Male</subject><subject>Malondialdehyde</subject><subject>Neutrophils</subject><subject>Oxidative stress</subject><subject>Physiology</subject><subject>Prednisolone</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Recombinant Proteins - pharmacology</subject><subject>Rodents</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkk9r3DAQxU1paUKaW89F0EtC143G9srWJVCW_INdCtv0bMby2KtgS1vJTrqfs1-oWna7TQuF6iLB_PTmDfOi6C3wjwDT6UXCQV4UiSxAJi-i4ySFLBaQwcvDO02PolPvH3g4BQguxevoKAVR5BmH4-jHvSMcejIDe9LDii1s1zrsrR90z86WpGxfaYOhfDv2aNiNQzN2Vm0GiheonF2vsCU2s501G_Yl_Bo7HLRp2TWqwboJW67Gto9nvpmwhabOtmTOGZqazcnY0GvX6bnuP8XO2V2_dvaRPLv6viant76x23bXg_ZMG7bEwb-JXjXYeTrd3yfR1-ur-9ltPP98czf7NI9VlsMQ50oKzJBIKZCQUKW4LORUNqCSmuoKVI0Km7riwCtAEFhBnogAyzyjKklPosud7nqseqpVMOOwK9fBF7pNaVGXf1aMXpWtfSxFwdM8y4LA2V7A2W8j-aHstVfUdWjIjr4MK0wSURRSBvT9X-iDHZ0J4wWK51JMgU8DNdlRYTHeO2oOZoCX28CU28CU-8AE_N3zAQ7wr3gE4MMOWGlT45P-TzkKDDX4m4YkLzKR_gQoGdgz</recordid><startdate>2019</startdate><enddate>2019</enddate><creator>Triantafillidis, John K.</creator><creator>Nomikos, Alexandros</creator><creator>Pittaras, Theodoros</creator><creator>Sideris, Michail</creator><creator>Korontzi, Maria</creator><creator>Chrysikos, Dimosthenis</creator><creator>Barbatis, Calypso</creator><creator>Papalois, Apostolos E.</creator><creator>Triantafyllidi, Eleni</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4398-7557</orcidid><orcidid>https://orcid.org/0000-0002-9115-232X</orcidid><orcidid>https://orcid.org/0000-0002-4199-6700</orcidid><orcidid>https://orcid.org/0000-0001-8339-7426</orcidid><orcidid>https://orcid.org/0000-0001-5738-535X</orcidid></search><sort><creationdate>2019</creationdate><title>Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats</title><author>Triantafillidis, John K. ; Nomikos, Alexandros ; Pittaras, Theodoros ; Sideris, Michail ; Korontzi, Maria ; Chrysikos, Dimosthenis ; Barbatis, Calypso ; Papalois, Apostolos E. ; Triantafyllidi, Eleni</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Colitis</topic><topic>Colitis - drug therapy</topic><topic>Colon</topic><topic>Colonies</topic><topic>Colony-stimulating factor</topic><topic>Disease Models, Animal</topic><topic>Euthanasia</topic><topic>Gastroenterology</topic><topic>Granulocyte Colony-Stimulating Factor - pharmacology</topic><topic>Granulocyte-macrophage colony stimulating factor</topic><topic>Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology</topic><topic>Granulocytes</topic><topic>Granulocytes - drug effects</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Inflammatory bowel disease</topic><topic>Inflammatory bowel diseases</topic><topic>Intestine</topic><topic>Lenograstim - pharmacology</topic><topic>Leukocytes (granulocytic)</topic><topic>Macrophage Colony-Stimulating Factor - pharmacology</topic><topic>Macrophages</topic><topic>Male</topic><topic>Malondialdehyde</topic><topic>Neutrophils</topic><topic>Oxidative stress</topic><topic>Physiology</topic><topic>Prednisolone</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Recombinant Proteins - pharmacology</topic><topic>Rodents</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Triantafillidis, John K.</creatorcontrib><creatorcontrib>Nomikos, Alexandros</creatorcontrib><creatorcontrib>Pittaras, Theodoros</creatorcontrib><creatorcontrib>Sideris, Michail</creatorcontrib><creatorcontrib>Korontzi, Maria</creatorcontrib><creatorcontrib>Chrysikos, Dimosthenis</creatorcontrib><creatorcontrib>Barbatis, Calypso</creatorcontrib><creatorcontrib>Papalois, Apostolos E.</creatorcontrib><creatorcontrib>Triantafyllidi, Eleni</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Database‎ (1962 - current)</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East &amp; Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Triantafillidis, John K.</au><au>Nomikos, Alexandros</au><au>Pittaras, Theodoros</au><au>Sideris, Michail</au><au>Korontzi, Maria</au><au>Chrysikos, Dimosthenis</au><au>Barbatis, Calypso</au><au>Papalois, Apostolos E.</au><au>Triantafyllidi, Eleni</au><au>Quinn, Frederick D.</au><au>Frederick D Quinn</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats</atitle><jtitle>BioMed research international</jtitle><addtitle>Biomed Res Int</addtitle><date>2019</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>8</epage><pages>1-8</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Background/Aim. Treatment with growth factors could be beneficial in both inflammatory bowel disease and experimental colitis. The aim of this study was to investigate the effect of Colony Stimulating Factor (CSF), and Recombinant Human (rHu) Granulocyte Stimulating Factor (GSF) in experimental colitis in rats. Methods. Experimental colitis was induced in 62 male Wistar rats, divided into 9 groups, using 2,4,6-trinitrobenzensulfonic acid (TNBS). Group 1: Ten rats with colitis without treatment (control group). Euthanasia after 15 days. Group 2: Ten animals with colitis without treatment (control group). Euthanasia after 30 days. Group 3: Six animals with colitis. Immediate treatment with CSF. Euthanasia after 19 days. Group 4: Six animals with colitis. Treatment started 7 days after the induction of colitis. Animals were kept for 19 days. Group 5: Six animals with colitis. Treatment started 2 weeks after the induction of colitis. Group 6: Six animals with colitis, the same as in group 3. Treatment with GSF. Group 7: Six animals with colitis, the same as in group 4. Treatment with GSF. Group 8. Six animals with colitis, the same as in group 5. Treatment with GSF. Group 9: Six animals with colitis. Immediate treatment with prednisolone. Euthanasia after 15 days. Results. CSF and GSF administration significantly improved the histological score (P&lt;0.05) and reduced malondialdehyde contents (P&lt;0.05), compared to control groups in all animals. CSF was superior to GSF and to prednisolone. Conclusion. Administration of both CSF and GSF could significantly improve the histological score and oxidative stress in experimental colitis in rats.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>31687401</pmid><doi>10.1155/2019/8298192</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4398-7557</orcidid><orcidid>https://orcid.org/0000-0002-9115-232X</orcidid><orcidid>https://orcid.org/0000-0002-4199-6700</orcidid><orcidid>https://orcid.org/0000-0001-8339-7426</orcidid><orcidid>https://orcid.org/0000-0001-5738-535X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2314-6133
ispartof BioMed research international, 2019, Vol.2019 (2019), p.1-8
issn 2314-6133
2314-6141
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6803744
source Wiley Online Library Open Access; Publicly Available Content Database
subjects Animals
Colitis
Colitis - drug therapy
Colon
Colonies
Colony-stimulating factor
Disease Models, Animal
Euthanasia
Gastroenterology
Granulocyte Colony-Stimulating Factor - pharmacology
Granulocyte-macrophage colony stimulating factor
Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology
Granulocytes
Granulocytes - drug effects
Growth factors
Humans
Inflammatory bowel disease
Inflammatory bowel diseases
Intestine
Lenograstim - pharmacology
Leukocytes (granulocytic)
Macrophage Colony-Stimulating Factor - pharmacology
Macrophages
Male
Malondialdehyde
Neutrophils
Oxidative stress
Physiology
Prednisolone
Rats
Rats, Wistar
Recombinant Proteins - pharmacology
Rodents
title Treatment with Molgramostim (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor, Rhugm-Csf, Mielogen) and Lenograstim (Granulocyte-Colony Stimulating Factor) Improves Experimental Colitis in Rats
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T21%3A49%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20with%20Molgramostim%20(Recombinant%20Human%20Granulocyte-Macrophage%20Colony%20Stimulating%20Factor,%20Rhugm-Csf,%20Mielogen)%20and%20Lenograstim%20(Granulocyte-Colony%20Stimulating%20Factor)%20Improves%20Experimental%20Colitis%20in%20Rats&rft.jtitle=BioMed%20research%20international&rft.au=Triantafillidis,%20John%20K.&rft.date=2019&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=8&rft.pages=1-8&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2019/8298192&rft_dat=%3Cproquest_pubme%3E2307965105%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c471t-7c96a4aeecc1912ebc098959f1c2dedb1cdacafdb010b1a16ab1726c19974eb23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2307965105&rft_id=info:pmid/31687401&rfr_iscdi=true